title: QbD approach of rapid disintegrating tablets incorporating indomethacin solid dispersion.
abstract: The development of rapid disintegrating tablets (RDT) requires the use of highly soluble components to support the intended use of these products. In an attempt to prepare RDT of indomethacin, its solid dispersion with polyvinyl pyrrolidone K25 (PVP) was incorporated in a fast disintegrating matrix. Drug polymer interactions were investigated using X-ray diffraction (XRD) and Fourier transform infrared spectroscopy (FTIR). Indomethacin 1:1 solid dispersion with PVP was used to prepare its RDT. Two factors at 3 levels full factorial design were employed as a statistical approach to optimize the amount of superdisintegrant (Ac-di-sol) and hardness value regarding the desired disintegration and release characteristics. Drug to carrier ratio was the controlling factor for dissolution improvement. XRD and FTIR data revealed a remarkable interaction between the drug and the carrier that might be responsible for the dissolution enhancement. Multiple regression analysis revealed a significant effect of the polynomial terms for obtaining rapid disintegrating tablets. It was inferred that the hardness value is the most important factor controlling the disintegration time and the release characteristics. In conclusion, this study demonstrated that quality by design (QbD) is a potential paradigm for understanding the quality and optimizing the formulation of RDT containing indomethacin solid dispersion.
authors.affiliation: Department of Drug Technology, Faculty of Pharmacy, Ain Sahms University, Cairo, Egypt.
authors.forename: Omaima A
authors.initials: OA
authors.lastname: Sammour
authors.forename: Mohammed A
authors.initials: MA
authors.lastname: Hammad
authors.forename: Ahmed S
authors.initials: AS
authors.lastname: Zidan
authors.forename: Ayman G
authors.initials: AG
authors.lastname: Mowafy
mesh_terms: D002626:Chemistry, Pharmaceutical; D004337:Drug Carriers / Q000737:chemistry*; D004355:Drug Stability; D006244:Hardness; D006801:Humans; D007213:Indomethacin / Q000008:administration & dosage / Q000737:chemistry; D007700:Kinetics; D011205:Povidone / Q000008:administration & dosage / Q000737:chemistry; D012995:Solubility; D017550:Spectroscopy, Fourier Transform Infrared; D013607:Tablets / Q000737:chemistry; D014961:X-Ray Diffraction
chemical_list: D004337:Drug Carriers; D013607:Tablets; D011205:Povidone; D007213:Indomethacin